Please provide your email address to receive an email when new articles are posted on . Adding bimagrumab 30 mg/kg to semaglutide 2.4 mg conferred weight loss of more than 20% at 72 weeks in patients ...

PLANEGG/MUNICH, GERMANY / ACCESSWIRE / November 11, 2019 / MorphoSys AG (FSE: MOR; Prime Standard Segment; MDAX & TecDAX; NASDAQ: MOR) announced today that its licensee Novartis presented phase 2 ...

Weight loss medications have gained widespread popularity and have assisted many people in managing their weight. However, for some individuals, substantial weight loss can result in a reduction of ...

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that its collaborator Novartis has initiated a phase 2/3 clinical trial in sporadic inclusion body myositis (sIBM) ...

For the past three years, nearly every breakthrough in obesity medicine has traced back to a single class of drugs: GLP-1 receptor agonists like semaglutide and tirzepatide. Now, a phase 2 clinical ...

Scientists have found that an antibody treatment prevented a decline in muscle mass and bone density after using GLP-1 drugs. Rob and Julia Campbell/Stocksy Studies suggest that weight loss induced by ...

A new study has found that combining two weight-loss drugs, Eli Lilly's experimental drug bimagrumab and Novo Nordisk's Wegovy, which contains semaglutide, helps people lose weight while keeping their ...

NEW YORK, June 11, 2022 /PRNewswire/ -- Versanis Bio ("Versanis"), a clinical-stage company advancing novel therapeutics for cardiometabolic diseases, will share analysis of Phase 2 data from prior ...

Add Yahoo as a preferred source to see more of our stories on Google. GLP-1 drugs like Ozempic and Zepbound are great at promoting weight loss, but they also cause folks to lose muscle along with fat, ...

Share on Pinterest Scientists have found that an antibody treatment prevented a decline in muscle mass and bone density after using GLP-1 drugs. Rob and Julia Campbell/Stocksy Aging and limited ...

MorphoSys AG has announced that its collaborator Novartis has initiated a phase 2/3 clinical trial in sporadic inclusion body myositis (sIBM) patients with the HuCAL-derived antibody bimagrumab ...